Marilyn Bonfili, MD
Family Medicine · Fairmont, WVNPI 1699775247
Payments from drug & device makers
Across 696 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Amgen$1K
- Lilly USA, LLC$904
- AstraZeneca$832
- Pfizer$697
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,52698%
- Education$1802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $2,057 |
| Novo Nordisk | 68 | $1,327 |
| Amgen | 63 | $1,040 |
| Lilly USA, LLC | 58 | $904 |
| AstraZeneca | 50 | $832 |
| Pfizer | 37 | $697 |
| Astellas Pharma US Inc | 35 | $640 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $525 |
| Boehringer Ingelheim | 34 | $503 |
| Bayer | 21 | $343 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $321 |
| Sanofi-aventis U.S. LLC | 20 | $302 |
| Exact Sciences | 17 | $277 |
| Merck | 17 | $216 |
| Kowa Pharmaceuticals America, Inc. | 15 | $198 |
| Johnson & Johnson | 11 | $191 |
| Abbott | 9 | $188 |
| GSK | 11 | $164 |
| Amarin Pharma, Inc. | 8 | $128 |
| E.r. Squibb & Sons, L.L.C. | 9 | $123 |
| Medtronic | 3 | $121 |
| Eisai Inc. | 5 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $76 |
| Tanabe Pharma America, Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $65 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Organon | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Novartis | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$11,705 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $49,956 |
| EliquisApixaban | 50 | $45,126 |
| OzempicSemaglutide | 24 | $29,167 |
| TrulicityDulaglutide | 28 | $25,539 |
| MounjaroTirzepatide | 22 | $24,314 |
| JanuviaSitagliptin Phosphate | 13 | $21,142 |
| FarxigaDapagliflozin Propanediol | 18 | $18,159 |
| RybelsusSemaglutide | 14 | $17,982 |
| XareltoRivaroxaban | 16 | $17,451 |
| LinzessLinaclotide | 17 | $15,320 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $14,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,451 |
| EntrestoSacubitril/Valsartan | 11 | $9,637 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,660 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $5,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $503 | $49,95641 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $904 | $49,85350 claims |
| Novo NordiskOzempic, Rybelsus | $1,327 | $47,14938 claims |
| PfizerEliquis | $697 | $45,12650 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $832 | $26,81832 claims |
| MerckJanuvia | $216 | $21,14213 claims |
| AbbVieLinzess, Synthroid | $2,057 | $17,49053 claims |
| Johnson & JohnsonXarelto | $191 | $17,45116 claims |
| GSKTrelegy Ellipta | $164 | $11,45118 claims |
| NovartisEntresto | $15 | $9,63711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Fairmont
- Lisa FlowerFairmont$11K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.